Upexi (NASDAQ:UPXI) Stock Rating Upgraded by Cantor Fitzgerald

Key Points

• Cantor Fitzgerald upgraded Upexi's stock rating to "strong-buy," reflecting positive outlook and confidence in the company's performance.
• Upexi's shares increased by 17.6%, with current trading around $7.83 and significant fluctuation over the past year, showing a high of $22.57 and a low of $1.90.
• Recent insider transactions indicate strong confidence as both the director and CEO purchased significant shares, leading to an increase in their ownership stakes.

Upexi (NASDAQ:UPXI - Get Free Report) was upgraded by equities researchers at Cantor Fitzgerald to a "strong-buy" rating in a note issued to investors on Wednesday,Zacks.com reports.

Several other equities research analysts have also recently commented on the company. Alliance Global Partners initiated coverage on Upexi in a research note on Monday, August 4th. They issued a "buy" rating and a $15.00 price target for the company. Wall Street Zen upgraded shares of Upexi to a "hold" rating in a research note on Friday, May 30th.

Upexi Stock Up 17.6%

Shares of NASDAQ UPXI opened at $7.83 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.24 and a current ratio of 0.37. Upexi has a one year low of $1.90 and a one year high of $22.57. The business has a 50-day moving average price of $6.69 and a two-hundred day moving average price of $6.09.

Upexi (NASDAQ:UPXI - Get Free Report) last posted its quarterly earnings results on Friday, May 16th. The company reported ($2.87) earnings per share (EPS) for the quarter. The company had revenue of $3.16 million during the quarter. Upexi had a negative return on equity of 535.19% and a negative net margin of 135.86%.

Insiders Place Their Bets

In related news, Director Gene Salkind purchased 20,243 shares of Upexi stock in a transaction on Friday, July 11th. The stock was bought at an average price of $4.94 per share, with a total value of $100,000.42. Following the completion of the transaction, the director directly owned 385,370 shares of the company's stock, valued at approximately $1,903,727.80. This represents a 5.54% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Allan Marshall purchased 161,943 shares of the firm's stock in a transaction dated Friday, July 11th. The shares were bought at an average price of $4.94 per share, with a total value of $799,998.42. Following the purchase, the chief executive officer owned 1,046,261 shares in the company, valued at $5,168,529.34. This represents a 18.31% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired 198,186 shares of company stock valued at $997,759 over the last three months. 31.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Upexi

Several hedge funds and other institutional investors have recently added to or reduced their stakes in UPXI. Bank of Montreal Can bought a new position in shares of Upexi in the fourth quarter worth about $36,000. North Star Investment Management Corp. bought a new stake in Upexi during the 2nd quarter valued at approximately $45,000. Millington Financial Advisors LLC acquired a new stake in Upexi in the 2nd quarter valued at approximately $60,000. XTX Topco Ltd acquired a new stake in Upexi in the 2nd quarter valued at approximately $249,000. Finally, Geode Capital Management LLC bought a new position in Upexi in the 2nd quarter worth approximately $1,002,000. Institutional investors and hedge funds own 5.68% of the company's stock.

Upexi Company Profile

Upexi, Inc manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc and changed its name to Upexi, Inc in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.